Finance

Beta
Lists
ORKA:NASDAQ
Oruka Therapeutics Inc
$90.60
+4.58%
(+3.97) 1D
$90.50
-0.11% (-0.100)
After hours
Closed: Jun 26, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ORKA...
Open
$85.54
High
$91.12
Low
$85.20
Mkt. cap
5.46B
Avg. vol.
1.38M
Volume
4.73M
52-wk high
$91.12
52-wk low
$10.83
EPS
-$2.39
Beta
-0.29
Shares outstanding
60.31M
No. of employees
68
Open
$85.54
High
$91.12
Low
$85.20
Mkt. cap
5.46B
Avg. vol.
1.38M
Volume
4.73M
52-wk high
$91.12
52-wk low
$10.83
EPS
-$2.39
Beta
-0.29
Shares outstanding
60.31M
No. of employees
68
News stories
From sources across the web
About Oruka Therapeutics Inc
CEO-
Employees68
Founded2024
HeadquartersWestminster, Colorado, United States
SectorBiotechnology
Websiteorukatx.com
Analyst ratings
Based on 12 analysts giving stock ratings to ORKA in the past 3 months
Strong buy
Buy
12
Hold
0
Sell
0
12-month forecast
Based on 12 Wall Street analysts offering 12 month price targets for ORKA in the last 3 months.
Highest
Current $90.60
$200.00 (+120.75%)
Average
$148.20 (+63.58%)
Lowest
$100.00 (+10.38%)
Analyst
Recommendation
Action
Price target
Projected
Date
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
$120.00
+32.5%
06/23/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
$180.00
+98.7%
06/02/2026
Michael Yee
UBS
Buy
Reiterated
$100.00
+10.4%
06/02/2026
David Risinger
Leerink Partners
Buy
Reiterated
-
-
06/02/2026
Sam Slutsky
LifeSci Capital
Buy
Maintained
$125.00
+38%
05/23/2026
David Nierengarten
Wedbush
Buy
Maintained
$165.00
+82.1%
05/14/2026
Julian Harrison
BTIG
Buy
Maintained
$151.00
+66.7%
05/13/2026
Etzer Darout
Barclays
Buy
Reiterated
$160.00
+76.6%
05/13/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
05/13/2026
Alex Thompson CFA
Stifel Nicolaus
Buy
Maintained
$150.00
+65.6%
04/28/2026
Kaveri Pohlman
Clear Street
Buy
Maintained
$131.00
+44.6%
04/27/2026
Yatin Suneja
Guggenheim
Buy
Maintained
$200.00
+120.8%
04/27/2026
Martin Fan
Wedbush
Buy
Maintained
$85.00
-6.2%
04/15/2026
Roger Song
Jefferies
Buy
Maintained
$45.00
-50.3%
03/11/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
24.09M
28.99M
27.64M
29.14M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.34M
5.12M
6.79M
7.29M
Operating expense
28.43M
34.10M
34.43M
36.43M
Total operating expenses
28.43M
34.10M
34.43M
36.43M
Operating income
-28.43M
-34.10M
-34.43M
-36.43M
Other non operating income
-2.00K
-4.00K
-1.00K
8.00K
EBT including unusual items
-24.57M
-30.28M
-29.58M
-31.82M
EBT excluding unusual items
-24.57M
-30.28M
-29.58M
-31.82M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-24.57M
-30.28M
-29.58M
-31.82M
Net profit margin
-
-
-
-
Earnings per share
-0.46
-0.55
-0.45
-0.48
Interest and investment income
3.86M
3.83M
4.85M
4.61M
Interest expense
-
-
-
-
Net interest expenses
3.86M
3.83M
4.85M
4.61M
Depreciation and amortization charges
-
-
-
-
EBITDA
-28.41M
-34.08M
-34.40M
-36.39M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
Give me an overview of ORKA
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer